Long-Term Renal and Cardiovascular Outcomes in Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Participants by Baseline Estimated GFR

被引:61
|
作者
Rahman, Mahboob [1 ]
Ford, Charles E. [1 ]
Cutler, Jeffrey A. [1 ]
Davis, Barry R. [1 ]
Piller, Linda B. [1 ]
Whelton, Paul K. [1 ]
Wright, Jackson T., Jr. [1 ]
Barzilay, Joshua I. [1 ]
Brown, Clinton D. [1 ]
Colon, Pedro J., Sr. [1 ]
Fine, Lawrence J. [1 ]
Grimm, Richard H., Jr. [1 ]
Gupta, Alok K. [1 ]
Baimbridge, Charles [1 ]
Haywood, L. Julian [1 ]
Henriquez, Mario A. [1 ]
Ilamaythi, Ekambaram [1 ]
Oparil, Suzanne [1 ]
Preston, Richard [1 ]
机构
[1] Univ Texas Houston, Sch Publ Hlth, Houston, TX 77030 USA
关键词
CHRONIC KIDNEY-DISEASE; BLOOD-PRESSURE CONTROL; HYPERTENSIVE PATIENTS; PROGRESSION; ASSOCIATION; AMERICAN; DESIGN;
D O I
10.2215/CJN.07800811
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background and objectives CKD is common among older patients. This article assesses long-term renal and cardiovascular outcomes in older high-risk hypertensive patients, stratified by baseline estimated GFR (eGFR), and long-term outcome efficacy of 5-year first-step treatment with amlodipine or lisinopril, each compared with chlorthalidone. Design, setting, participants, & measurements This was a long-term post-trial follow-up of hypertensive participants (n=31,350), aged >= 55 years, randomized to receive chlorthalidone, amlodipine, or lisinopril for 4-8 years at 593 centers. Participants were stratified by baseline eGFR (ml/min per 1.73 m(2)) as follows: normal/increased (>= 90; n=8027), mild reduction (60-89; n=17,778), and moderate/severe reduction (<60; n=5545). Outcomes were cardiovascular mortality (primary outcome), total mortality, coronary heart disease, cardiovascular disease, stroke, heart failure, and ESRD. Results After an average 8.8-year follow-up, total mortality was significantly higher in participants with moderate/severe eGFR reduction compared with those with normal and mildly reduced eGFR (P<0.001). in participants with an eGFR <60, there was no significant difference in cardiovascular mortality between chlorthalidone and amlodipine (P=0.64), or chlorthalidone and lisinopril (P=0.56). Likewise, no significant differences were observed for total mortality, coronary heart disease, cardiovascular disease, stroke, or ESRD. Conclusions CKD is associated with significantly higher long-term risk of cardiovascular events and mortality in older hypertensive patients. By eGFR stratum, 5-year treatment with amlodipine or lisinopril was not superior to chlorthalidone in preventing cardiovascular events, mortality, or ESRD during 9-year follow-up. Because data on proteinuria were not available, these findings may not be extrapolated to proteinuric CKD. Clin J Am Soc Nephrol 7: 989-1002, 2012. doi: 10.2215/CJN.07800811
引用
收藏
页码:989 / 1002
页数:14
相关论文
共 50 条
  • [11] Blood pressure control in the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)
    Cushman, WC
    Ford, CE
    Cutler, JA
    Margolis, KL
    Davis, BR
    Grimm, RH
    CIRCULATION, 2002, 106 (19) : 476 - 476
  • [13] Baseline Quality of Life and Risk of Stroke in the ALLHAT Study (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial)
    Shams, Tanzila
    Auchus, Alexander P.
    Oparil, Suzanne
    Wright, Clinton B.
    Wright, Jackson
    Furlan, Anthony J.
    Sila, Cathy A.
    Davis, Barry R.
    Pressel, Sara
    Yamal, Jose-Miguel
    Einhorn, Paula T.
    Lerner, Alan J.
    STROKE, 2017, 48 (11) : 3078 - +
  • [14] Pharmacologic Prevention of Incident Atrial Fibrillation Long-Term Results From the ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial)
    Dewland, Thomas A.
    Soliman, Elsayed Z.
    Yamal, Jose-Miguel
    Davis, Barry R.
    Alonso, Alvaro
    Albert, Christine M.
    Simpson, Lara M.
    Haywood, L. Julian
    Marcus, Gregory M.
    CIRCULATION-ARRHYTHMIA AND ELECTROPHYSIOLOGY, 2017, 10 (12):
  • [15] The antihypertensive and lipid-lowering treatment to prevent heart attack trial
    Flack, JM
    Nasser, SA
    CURRENT HYPERTENSION REPORTS, 2003, 5 (03) : 189 - 191
  • [16] Atrial Fibrillation at Baseline and During Follow-Up in ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial)
    Haywood, L. Julian
    Ford, Charles E.
    Crow, Richard S.
    Davis, Barry R.
    Massie, Barry M.
    Einhorn, Paula T.
    Williard, Angela
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2009, 54 (22) : 2023 - 2031
  • [17] THE ANTIHYPERTENSIVE AND LIPID-LOWERING TREATMENT TO PREVENT HEART-ATTACK TRIAL (ALLHAT) - DESIGN AND INITIAL CHARACTERISTICS
    CUSHMAN, WC
    HYPERTENSION, 1995, 25 (06) : 1356 - 1356
  • [18] The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT): Clinical center recruitment experience
    Wright, JT
    Cushman, WC
    Davis, BR
    Barzilay, J
    Colon, P
    Egan, D
    Lucente, T
    Nwachuku, C
    Pressel, S
    Leenen, FHH
    Frolkis, J
    Letterer, R
    Walsh, S
    Tobin, JN
    Deger, GE
    CONTROLLED CLINICAL TRIALS, 2001, 22 (06): : 659 - 673
  • [19] Effect of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) on Conduction System Disease
    Dewland, Thomas A.
    Soliman, Elsayed Z.
    Davis, Barry R.
    Magnani, Jared W.
    Yamal, Jose-Miguel
    Piller, Linda B.
    Haywood, L. Julian
    Alonso, Alvaro
    Albert, Christine M.
    Marcus, Gregory M.
    JAMA INTERNAL MEDICINE, 2016, 176 (08) : 1085 - 1092
  • [20] Mortality and morbidity during and after the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)
    Probstfield, J. L.
    Cushman, W. C.
    Davis, B. R.
    Pressel, S.
    Cutler, J. A.
    Einhorn, P.
    Ford, C.
    Oparil, S.
    Whelton, P.
    Wright, J. T.
    EUROPEAN HEART JOURNAL, 2010, 31 : 321 - 321